# A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis

> **NCT06999733** · PHASE1,PHASE2 · RECRUITING · sponsor: **Krystal Biotech, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Neurotrophic Keratitis

## Interventions

- **BIOLOGICAL:** KB801
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06999733
- **Lead sponsor:** Krystal Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-07
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06999733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06999733, "A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06999733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*